Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tilray Brands, Inc. - Common Stock (NQ:TLRY)

0.4216 +0.0072 (+1.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Tilray Brands, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Rumble, Tilray, Occidental Petroleum And More: 5 Stocks Retailers On Stocktwits Are Most Bullish About At Start Of Trading Week
Carson Group's Ryan Detrick said, “With stocks extremely oversold going into this historically strong time of year, we’d expect to see a bounce to close out a solid year for investors in 2024.” 
Via Stocktwits
Tilray's CEO Makes a Bold Prediction: Is the Stock a Buy?
Via The Motley Fool
Better Marijuana Stock: Aurora Cannabis or Tilray Brands?
Via The Motley Fool
Topics Cannabis
How Is The Market Feeling About Tilray Brands?
Via Benzinga
Is Tilray Brands Stock a Buy?
Via The Motley Fool
Tilray Introduces New Indica Strain With 'Potent THC And A Unique Terpene Profile'
Via Benzinga
1 Stock to Avoid After the Election Results
Via The Motley Fool
EXCLUSIVE: Drug Expert Dr. Carl Hart Slams Cannabis Prohibition Amid Hemp-THC Surge
Dr. Carl Hart discusses hemp THC, unregulated markets, and the need for federal cannabis legalization to reduce risks and protect consumers. 
Via Benzinga
Topics Cannabis
Are You Missing Out On This NASDAQ-Listed Weed Stock? Low-Cost Model Meets European Demand
Beyond Canada, this global cannabis company is focused on its international business, particularly in Germany, Australia, and the UK. 
Via Benzinga
Topics Cannabis
Decibel Cannabis: One Acquisition Could Be The Key To Unlocking $20M In Cash Flow
Decibel, a leading Canadian pre-roll franchise, may trade closer to larger market-cap cannabis stocks, according to analyst Pablo Zuanic. 
Via Benzinga
Topics Cannabis
If You'd Invested $1,000 in Tilray Stock 6 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Down 40% This Year, Is Tilray Brands Stock Due for a Much Better Performance in 2025?
Via The Motley Fool
How Is The Market Feeling About Tilray Brands?
Via Benzinga
Three Reasons to Avoid TLRY and One Stock to Buy Instead
What a brutal six months it’s been for Tilray. The stock has dropped 22% and now trades at $1.42, rattling many shareholders. This was partly driven by its softer quarterly results and may have... 
Via StockStory
Topics Cannabis
Meta Faces Multibillion-Dollar Lawsuit As Supreme Court Dismisses Appeal In Cambridge Analytica Data Scandal
Meta Platforms faces a multibillion-dollar lawsuit after the U.S. Supreme Court dismissed its appeal over the Cambridge Analytica data scandal, potentially leading to a $2 billion settlement. 
Via Benzinga
Topics Lawsuit
German Cannabis: 20 Tons, 10M Grams - And That's Only 0.3% Of The Market, What's Missing?
Medical cannabis users still represent less than 0.3% of the population, indicating significant potential for market expansion. 
Via Benzinga
Topics Cannabis
Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General Nominee
The AdvisorShares Pure US Cannabis ETF (NYSEARCA: MSOS), often viewed as a benchmark for MSOs, dropped by -4.31%, closing at $4.56. 
Via Benzinga
Topics Cannabis ETFs Government
Prediction: Tilray Brands Won't Be a Cannabis Company in 5 Years
Via The Motley Fool
Topics Cannabis
These 2 Marijuana Stocks Could Surge Under Trump's Second Term
Via The Motley Fool
Topics Cannabis Government
Beverages, Alcohol and Tobacco Stocks Q3 Recap: Benchmarking Tilray Brands (NASDAQ:TLRY)
Looking back on beverages, alcohol and tobacco stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Tilray Brands (NASDAQ:TLRY) and its peers. 
Via StockStory
Topics Cannabis
Q3 Earnings Outperformers: Celsius (NASDAQ:CELH) And The Rest Of The Beverages, Alcohol and Tobacco Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Celsius (NASDAQ:CELH) and the best and worst... 
Via StockStory
Topics Cannabis
Shareholder Lawsuit Challenges Tilray's Voting Tactics For Authorized Share Increase
Tilray faces a new shareholder lawsuit accusing the company of misleading voting practices, following a $39.9M settlement over similar issues 
Via Benzinga
Topics Lawsuit
Tilray Joins German Cannabis Fiesta With First Locally Grown Strains
Tilray Medical launches its first German-grown cannabis products under a new cultivation license, tapping into Germany's expanding market... 
Via Benzinga
Topics Cannabis
CBD Pioneer Charlotte's Web Narrows Loss In Q3, Focuses On Long-Term Growth
Charlotte's Web Holdings, Inc. (TSX: CWEB) (OTCQX: CWBHF) a producer of hemp-derived CBD and other botanical wellness products, reported on Thursday financial results for the third quarter ended Sept.... 
Via Benzinga
Does the Rejection of Top Marijuana Legalization Measures Doom the Pot Industry?
The American electorate seems to have turned against weed legal reform. 
Via The Motley Fool
Topics Cannabis
Cannabis Stocks Pop Following Chris Christie's Prediction That Trump Will Deschedule Cannabis
Cannabis stocks rally on prediction of Trump descheduling marijuana; MSOS leads gains with a 15% surge, followed by Cronos at nearly 13%. 
Via Benzinga
Topics Cannabis Government
Cannabis Stocks: Is It Time To Buy The Dip After Elections And Legalization Setbacks?
After a post-election plunge, cannabis stocks are showing signs of recovery. We analyze Tilray, SNDL, Trulieve, MSOS – time to buy the dip? 
Via Benzinga
Topics Cannabis
Aurora vs. Canopy & Tilray: Which NASDAQ-Listed Cannabis Stock Offers The Best Growth Potential?
Aurora's international medical cannabis business bolstered its results, with European sales doubling quarter-over-quarter. 
Via Benzinga
Topics Cannabis
Cannabis Extract Significantly Reduces Chemotherapy-Induced Vomiting, Tilray-Backed Study Reveals
Via Benzinga
Topics Cannabis
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.